Reviewing BioPharmX Corporation (BPMX)’s and Rafael Holdings Inc. (NYSEAMERICAN:RFL)’s results

BioPharmX Corporation (NYSEAMERICAN:BPMX) and Rafael Holdings Inc. (NYSEAMERICAN:RFL) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioPharmX Corporation 1 357.76 N/A -2.02 0.00
Rafael Holdings Inc. 18 69.30 N/A -0.08 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 provides us BioPharmX Corporation and Rafael Holdings Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
BioPharmX Corporation 0.00% -870.1% -334.1%
Rafael Holdings Inc. 0.00% -3.3% -2.9%

Institutional and Insider Ownership

Roughly 16.1% of BioPharmX Corporation shares are held by institutional investors while 36.3% of Rafael Holdings Inc. are owned by institutional investors. Insiders held 1.64% of BioPharmX Corporation shares. Comparatively, insiders own roughly 11.59% of Rafael Holdings Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
BioPharmX Corporation -4.63% -27.88% -66.62% -83.71% -91.86% -84.41%
Rafael Holdings Inc. -2.59% -23.36% 27.78% 21.34% 126.97% 161.03%

For the past year BioPharmX Corporation had bearish trend while Rafael Holdings Inc. had bullish trend.

Summary

On 6 of the 7 factors Rafael Holdings Inc. beats BioPharmX Corporation.

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and womenÂ’s health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and for the alleviation of symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX03, a molecular iodine tablet, which is in pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia; and BPX01, a topical antibiotic gel that is in Phase IIb clinical trial for the treatment of acne vulgaris. The company is also developing BPX02, an injectable product for aesthetic dermatology applications. It serves pharmaceutical companies; physicianÂ’s practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. The company has collaboration and licensing agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. BioPharmX Corporation is headquartered in Menlo Park, California.

Rafael Holdings, Inc. holds commercial real estate assets. The company, through its subsidiaries, focuses on the development and commercialization of oncology drugs. Rafael Holdings, Inc. is based in Newark, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.